## CLAIMS

WHAT IS CLAIMED IS:

1. A pharmaceutical composition, comprising:

(i) particles of a compound of Formula (I):



(I),

or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein the particles of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof are micronized and at least 90% of the particles have a diameter of from 0.1 μm to 40 μm; and

(ii) at least one pharmaceutically acceptable excipient,

wherein the pharmaceutical composition is in a dosage form for ophthalmic dosing or administration and is formulated as a suspension.

2. The composition of claim 1, wherein the particles of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof have a diameter of from 0.1 μm to 10 μm, or from 0.3 μm to 5 μm.
3. The composition of claim 1 or 2, wherein at least 95% of the particles have a diameter of from 0.1 μm to 40 μm.
4. The composition of claim 1 or 2, wherein the particles have a D50 value of less than 5 μm.
5. The composition of any one of claims 1-4, wherein the dosage form is a modified-release dosage form.
6. The composition of any one of claims 1-5, wherein the composition comprises from 0.025% to 2.0% w/v, 0.05% to 0.5% w/v, or 0.05% to 0.15% w/v of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.
7. The composition of any one of claims 1-6, wherein the at least one pharmaceutically acceptable excipient is a diluent, buffering agent, suspending agent, a wetting agent, solubilizer, emulsifier, antioxidant, pH adjuster, an anti-oxidant, an osmotic pressure regulator, preservative, detackifier, anti-foaming agent, chelating agent, thickening agent,

viscomodulator, tonicifier, colorant, opacifier, binder, filler, plasticizer, or any combination thereof.

8. The composition of claim 7, wherein the suspending agent is a carbomer homopolymer, carbomer copolymer, carbomer interpolymer, polycarbophil, a cellulose derivative, a polyvinyl alcohol, a povidone, a hyaluronic acid or a salt thereof, chondroitin sulfate, a natural gum, or any combination thereof.
9. The composition of claim 8, wherein the concentration of the suspending agent in the compositions is up to 1% w/w or 0.5% w/w.
10. The composition of any one of claims 7-9, wherein the wetting agent is polyoxyl 15-hydroxystearate.
11. The composition of claim 7 or 8, wherein the pH adjuster is a buffer.
12. The composition claim 11, wherein the buffer is a phosphate buffer selected from potassium phosphate, sodium dihydrogen phosphate dihydrate ($NaH_2PO_4 \cdot 2H_2O$), di-sodium hydrogen phosphate dodecahydrate ($Na_2HPO_4 \cdot 12H_2O$), or a combination thereof, or a hydrate thereof.
13. The composition of claim 7, wherein the osmotic pressure regulator is sodium chloride.
14. The composition of any one of claims 7-13, wherein the anti-oxidant is a thiosulfate.
15. The composition of claim 14, wherein the thiosulfate is sodium thiosulfate.
16. The composition of claim 14 or 15, wherein the concentration of the anti-oxidant in the composition is up to 0.2% w/w.
17. The composition of any one of claims 1-16, wherein the composition is stable for up to 24 months at a temperature of from 20 °C to 25 °C.

18. The composition of any one of claims 1-17, wherein the composition comprises up to 2% w/w of total impurities, wherein the impurity is a degradant of the compound of Formula (I).
19. The composition of any one of claims 1-17, wherein the impurity comprises the compound of Formula (II):




(II).

20. The composition of claim 18 or 19, wherein the composition comprises less than 0.9% w/w, 0.8% w/w, 0.7% w/w, 0.6% w/w, 0.5% w/w, 0.4% w/w, 0.3% w/w, 0.2% w/w, or 0.1% w/w of total impurities.

21. The composition of any one of claims 1-20, wherein the composition has a pH of from 4.0 to 9.0, or 5.0 to 8.0, or 6.5 to 8.0, or 7.0 to 8.0.

22. A method of preparing the composition of any one of claims 1-21, comprising:

(i) micronizing the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof;

(ii) sterilizing the micronized compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and

(iii) admixing a therapeutically effective amount of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof with the least one pharmaceutically acceptable excipients.

23. The method of claim 22, wherein a suspension comprising particles of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is formed.

24. The method of claim 22 or 23, wherein the sterilization is performed at a temperature of about 121 °C.

25. The method of any one of claims 22-24, wherein the sterilization is performed for a period of from 20 to 30 minutes.